12-weeks, Multicentre, Randomized, Double-blind, Placebo-controlled, Exploratory, Pilot Study to Evaluate the Safety and Efficacy of Safinamide 200 mg OD, as add-on Therapy, in Patients With Possible or Probable Parkinsonian Variant of MSA
Phase: PHASE2
Conditions: Multiple System Atrophy
Sponsor: Zambon SpA

 
 
 
16. 
APPENDICES 
APPENDIX 16.1: 
STUDY INFORMATION 
APPENDIX 16.1.1: PROTOCOL AND PROTOCOL AMENDMENTS 
Summary of Changes for Protocol Amendment 01, 13 July 2020 ................................................. 2 
Protocol Amendment 01, Version 2.0, 13 July 2020 .................................................................... 10 
Protocol Administrative Letter #1, 09 August 2019 ..................................................................... 71 
Original Protocol, Version 1.0, 21 February 2019 ........................................................................ 75